Business Wire

TVP-SOLAR

Share
PepsiCo Implements TVP Solar Thermal Plant for Renewable Heat and Saves 140’000 M³ of Natural Gas at the Sete Lagoas Factory (MG)

PepsiCo, one of the largest food and beverage companies in the world, implemented an innovative project in its Sete Lagoas (MG) snacks operation: a solar thermal plant that captures sunlight and converts it into thermal energy for heating process water. Through this technology, it was possible to reduce natural gas consumption by 140’000 m³ in the unit - which will also reduce greenhouse gas (GHG) emissions by almost 280 tons . This number is equivalent to the planting of almost 18’000 trees.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220127005027/en/

The thermo-solar plant is made up of high-vacuum solar thermal flat panels, running automatically, without supervision and without the need for cleaning. The first results show that the plant generated about 3.9 kWh/m²/day of thermal energy during the summer months, providing hot water at 60-75°C, even in the dry climate of Sete Lagoas. The energy targets were hit. The water heated by the system is used in several factory processes. “To give an example, we use the water heated by the thermo solar system to cook the corn in our snacks. The difference is that the water is already heated to the process, so we have to use less flame time to reach the temperature we use at this stage of production” , describes Bruno Guerreiro, Sustainability Manager at PepsiCo Brazil.

With the new solar thermal plant, PepsiCo moves towards its global goal of reducing carbon emissions by 40% by 2030 (2015 baseline) and Net-zero by 2040. “It is an important innovation to use thermal energy from the solar plant in the country. With this initiative, we became more sustainable, a premise that is at the heart of the way we do business at the company, continually seeking to evolve towards a Positive Value Chain” , explained Guerreiro. According to him, the solution is scalable and should be implemented in other PepsiCo Brazil plants in the coming years, with even larger areas of solar panels.

The solar thermal plant at the Sete Lagoas site is the result of a partnership between PepsiCo and TVP Solar, a Swiss company specializing in solar thermal technology with state-of-the-art solutions. TVP Solar designs, develops, manufactures and markets high vacuum, mirrorless solar thermal collectors based on patented technology. Solar thermal energy is carbon-free and a cheaper alternative than that generated by liquid fuels.

Piero Abbate, CEO of TVP Solar, highlights that the partnership with PepsiCo is emblematic for the company, because it highlights the importance of solar thermal energy for the food and beverage industry. “We hope this will be the beginning of a long-term collaboration with PepsiCo,” says Piero.

In 2021, PepsiCo announced the launch of the PepsiCo Positive (pep+) platform, which puts sustainability at the heart of how the company creates growth and value, operating within the limits of the planet and inspiring positive change for the environment and people. As a result, sustainability starts to guide the way PepsiCo operates its business: from sourcing ingredients, manufacturing and selling its products in a more sustainable way, to inspiring people to make choices that are better for themselves and the planet. “Our solar thermal plant is another step on our journey towards sustainability. We are constantly evolving in our processes and innovating on several fronts to do our part to contain climate change, reducing greenhouse gas (GHG) emissions throughout our value chain” , said the CEO of PepsiCo Brasil Alimentos, Alex Carretero .

To learn more about the PepsiCo Positive agenda, visit

https://www.pepsico.com.br/sustentabilidade/pepsicopositive .

About PepsiCo

PepsiCo products are enjoyed more than a billion times a day by consumers in more than 200 countries and territories worldwide. PepsiCo generated more than $70 billion in global net revenue in 2020, driven by a complementary food and beverage portfolio that, in Brazil, includes PEPSI®, GATORADE®, QUAKER®, LAY'S®, DORITOS®, RUFFLES®, CHEETOS ®, KERO COCO®, H2OH!®, TODDY® among others. PepsiCo's product portfolio includes a broad range of food and beverage products, including 23 brands that generate more than $1 billion each in estimated annual sales.

PepsiCo is guided by the vision of Being the Global Leader in Convenient Food and Beverages by Winning with Purpose, which reflects our drive to win sustainably in the marketplace and embed purpose in all aspects of the business. For more information, visit www.pepsico.com.br .

About TVP Solar :

TVP Solar SA is a Swiss company which designs, develops, manufactures and markets innovative high-vacuum solar thermal collectors based on patented technology. TVP revolutionized solar thermal, decarbonizing industrial processes in large-scale deployments. TVP has been installed across 9 countries and 3 continents, supplying carbon-free renewable heat, the cheapest thermal energy cutting OPEX and CO2 emissions, while securing energy supply. For more information please visit: www.tvpsolar.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release

Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release

SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f

Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release

Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr

IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release

Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye